Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Pal, Sumanta K ^a   Dehaven, Mary ^a   Nelson, Rebecca A ^a   Onami, Susan ^a   Hsu, JoAnn ^a   Waliany, Sarah ^a   Kruper, Laura ^a   Mortimer, Joanne ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Endocrine therapy; Metastatic breast cancer; Stage IV; Survival

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; GONADORELIN DERIVATIVE; IFOSFAMIDE; IXABEPILONE; METHOTREXATE; NAVELBINE; PACLITAXEL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; SURVIVAL PREDICTION; SURVIVAL TIME;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CALIFORNIA; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866660433     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-435     Document Type: Article

References (14)

1. Early Breast Cancer Trialists' Collaborative G Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444. Early Breast Cancer Trialists' Collaborative G.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
3. Cortazar P, Zhang JJ, Sridhara R, Justice RL, Pazdur R. Relationship between OS and PFS in metastatic breast cancer (MBC): Review of FDA submission data. ASCO Meeting Abstracts 2011, 29:1035.
4. Montero AJ, Vogel C. Fighting Fire with Fire: Rekindling the Bevacizumab Debate. N Engl J Med 2012, 366:374-375. 10.1056/NEJMe1113368, 22276827.
5. Andre F, Slimane K, Bachelot T, et al. Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. J Clin Oncol 2004, 22:3302-3308. 10.1200/JCO.2004.08.095, 15310773.
6. Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007, 110:973-979. 10.1002/cncr.22867, 17647245.
7. Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010, 119:621-631. 10.1007/s10549-009-0630-8, 19915976.
8. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2008, 26:4891-4898. 10.1200/JCO.2007.14.1168, 2736998, 18725649.
9. Giordano SH, Buzdar AU, Smith TL, Kau S-W, Yang Y, Hortobagyi GN. Is breast cancer survival improving?. Cancer 2004, 100:44-52. 10.1002/cncr.11859, 14692023.
10. Ruiterkamp J, Ernst MF, de Munck L, et al. Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nationwide population-based study in the Netherlands. Breast Cancer Res Treat 2011, 128:495-503. 10.1007/s10549-011-1349-x, 21240629.
11. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996, 14:2000-2011.
12. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000, 18:1399-1411.
13. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer. J Clin Oncol 2008, JCO.2007.14.1168.
14. Dafni U, Grimani I, Xyrafas A, Eleftheraki A, Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010, 119:621-31. 10.1007/s10549-009-0630-8, 19915976.